AR114627A1 - Composición inmunogénica - Google Patents

Composición inmunogénica

Info

Publication number
AR114627A1
AR114627A1 ARP190100345A ARP190100345A AR114627A1 AR 114627 A1 AR114627 A1 AR 114627A1 AR P190100345 A ARP190100345 A AR P190100345A AR P190100345 A ARP190100345 A AR P190100345A AR 114627 A1 AR114627 A1 AR 114627A1
Authority
AR
Argentina
Prior art keywords
immunogenic composition
antigen
capsular polysaccharide
staphylococcal
container
Prior art date
Application number
ARP190100345A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR114627A1 publication Critical patent/AR114627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ARP190100345A 2018-02-13 2019-02-12 Composición inmunogénica AR114627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition

Publications (1)

Publication Number Publication Date
AR114627A1 true AR114627A1 (es) 2020-09-30

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100345A AR114627A1 (es) 2018-02-13 2019-02-12 Composición inmunogénica

Country Status (15)

Country Link
US (2) US11426455B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752183A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021514387A (cg-RX-API-DMAC7.html)
KR (1) KR20200121825A (cg-RX-API-DMAC7.html)
CN (1) CN112153980A (cg-RX-API-DMAC7.html)
AR (1) AR114627A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019221496B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090609A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091690A1 (cg-RX-API-DMAC7.html)
GB (1) GB201802339D0 (cg-RX-API-DMAC7.html)
IL (1) IL276661B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008454A (cg-RX-API-DMAC7.html)
SG (1) SG11202007676RA (cg-RX-API-DMAC7.html)
WO (1) WO2019158537A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12673102B2 (en) 2020-05-01 2026-07-07 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技(武汉)有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
KR20220039610A (ko) 2020-09-21 2022-03-29 주식회사 엘지에너지솔루션 리튬 이차전지 활성화 방법 및 리튬 이차전지
CN121081612A (zh) * 2024-05-30 2025-12-09 江苏坤力生物制药有限责任公司 一种金黄色葡萄球菌纳米化抗原、含其的疫苗及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CA2713241C (en) * 2008-01-31 2022-10-04 Timothy Foster Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
AU2011274367B2 (en) * 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
CN106163550A (zh) 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12673102B2 (en) 2020-05-01 2026-07-07 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen

Also Published As

Publication number Publication date
SG11202007676RA (en) 2020-09-29
KR20200121825A (ko) 2020-10-26
EA202091690A1 (ru) 2020-11-27
BR112020016373A2 (pt) 2020-12-15
JP2021514387A (ja) 2021-06-10
CA3090609A1 (en) 2019-08-22
IL276661B2 (en) 2023-08-01
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
EP3752183A1 (en) 2020-12-23
US20230052495A1 (en) 2023-02-16
GB201802339D0 (en) 2018-03-28
US20210023192A1 (en) 2021-01-28
AU2019221496A1 (en) 2020-08-27
AU2019221496B2 (en) 2022-12-08
US11426455B2 (en) 2022-08-30
MX2020008454A (es) 2021-03-25
CN112153980A (zh) 2020-12-29
WO2019158537A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
AR003006A1 (es) Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
ES2166779T3 (es) Complejos inmunogenicos del hiv.
PE20212335A1 (es) Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
CY1112589T1 (el) Ανοσογονος συνθεση που περιεχει ανοσοενισχυτικο
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
ES2084827T3 (es) Composiciones de vacuna mejoradas.
PE20220220A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
BR112023023671A2 (pt) Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
NO20023829D0 (no) Proteosom influensavaksine
DK602989D0 (da) Saponinadjuvans
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
AR023535A1 (es) Nuevas composiciones.
MX2018015361A (es) Formulacion de vacuna contra el vih.
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
MX2022010129A (es) Composiciones inmunogenicas de streptococo del grupo a con conjugados de proteina de polisacaridos.
BR112022002094A2 (pt) Composição imunogênica
SE8702734D0 (sv) Monoclonal antibodies to pseudomonas aeruginosa flagella
CO2024004838A1 (es) Métodos para mejorar la adsorción de conjugados de polisacárido-proteína y formulación de vacuna multivalente obtenida de los mismos
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
EP0952771A4 (en) SAPONIN COMPOSITIONS AND THEIR USE
CU23244A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR127503A1 (es) Composiciones de gel inmunógenas que comprende antígeno de lawsonia intracellularis y/o antígeno de salmonella spp.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal